Regulacje i polityka gospodarcza · 15/11/1996

NIH to Grant Partially Exclusive License for Pseudomonas-Exotoxin-Based Cancer Therapy

The National Institutes of Health is considering granting a partially exclusive license to Boehringer-Mannheim Corporation for the use of a Pseudomonas-exotoxin-based fusion protein cancer therapy, as outlined in several U.S. patent applications.